Last reviewed · How we verify
Placebo intake once daily
Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous healing mechanisms and neurobiological pathways.
Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous healing mechanisms and neurobiological pathways. Used for Control arm in clinical trials, Conditions responsive to expectancy effects (e.g., pain, nausea, fatigue).
At a glance
| Generic name | Placebo intake once daily |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo effects are mediated by psychological expectation, conditioning, and activation of the central nervous system's natural pain-relief and healing pathways, including endogenous opioid and dopamine systems. The effect is not inert but involves measurable physiological changes in brain activity, neurotransmitter release, and immune function. Placebo is often used as a control in clinical trials but can itself produce clinically meaningful improvements in subjective symptoms.
Approved indications
- Control arm in clinical trials
- Conditions responsive to expectancy effects (e.g., pain, nausea, fatigue)
Common side effects
- Nocebo effects (adverse events due to negative expectation)
- Delayed treatment of underlying condition if used as sole therapy
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes (NA)
- Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (PHASE2)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (PHASE3)
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (PHASE3)
- Evaluation of HB05P for Muscle Strength Improvement in Older Adults (NA)
- Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo intake once daily CI brief — competitive landscape report
- Placebo intake once daily updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI